July 31, 2023

Dear Rett Community,

Today, Taysha announced that the Independent Data Monitoring Committee (IDMC) recommended continuation of the REVEAL Adult Study based on initial clinical data from the first adult with Rett syndrome who was dosed with the investigational gene therapy, TSHA-102. Initial clinical data on the first patient dosed with TSHA-102 is planned to be shared publicly in mid-August.

Please see below for a list of frequently asked questions.

**What is the REVEAL Adult Study?**
- The REVEAL Adult Study is a multi-center Phase 1/2 open-label dose-escalation clinical trial designed to evaluate the potential safety, tolerability, and preliminary efficacy of a single administration of the investigational gene therapy, TSHA-102, in adult females 18 years and older with Rett syndrome
- The study is designed to evaluate two different dose levels to determine the optimal amount (highest dose without harmful side effects) of TSHA-102

**What is the Independent Data Monitoring Committee (IDMC)?**
- The IDMC is an independent group of experts who monitor patient safety, potential efficacy and study conduct while a clinical trial is ongoing
- Taysha confers with the IDMC to make decisions related to key clinical activities, such as proceeding with dosing a second participant
- As announced today, the IDMC reviewed initial data from the first participant and recommended to proceed with dosing a second participant

**When will the second patient be dosed in the REVEAL Adult Study?**
- The dosing of a second participant is expected in the third quarter of 2023

**Where is the REVEAL Adult Study clinical trial being conducted?**
- The study is being conducted at CHU Sainte-Justine, the Université de Montréal mother and child university hospital centre in Montreal, Canada

If you have any additional questions or would like to connect with a member of our team, please contact medinfo@tayshagtx.com.

We would like to thank the entire Rett community and the Rett patient advocacy groups for your continued partnership. We look forward to providing further updates as new information becomes publicly available.

Sincerely,
The Taysha Patient Affairs Team

© Taysha Gene Therapies 2023. All rights reserved. TSHA-RET-273-2023